Luye Pharma Group Ltd.

Luye Pharma Group Ltd. logo
🇨🇳China
Ownership
Public
Established
2014-04-28
Employees
5.2K
Market Cap
-
Website
http://www.luye.cn

A Study of LY03005 vs Pristiq

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-11-07
Last Posted Date
2018-11-09
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
56
Registration Number
NCT03733574
Locations
🇺🇸

Pharmaron CPC, Inc., Baltimore, Maryland, United States

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-07-17
Last Posted Date
2018-11-08
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
24
Registration Number
NCT03589066
Locations
🇺🇸

MD Clinical, Hallandale Beach, Florida, United States

🇺🇸

Atlanta Center for Medical Research, Atlanta, Georgia, United States

A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

First Posted Date
2018-05-22
Last Posted Date
2018-07-10
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
648
Registration Number
NCT03533127
Locations
🇨🇳

Chinese Academy of Medical Sciences, Chaoyang, Beijing, China

A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-03-01
Last Posted Date
2019-01-07
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
19
Registration Number
NCT03450109
Locations
🇺🇸

Pinnacle Research LLC, Anniston, Alabama, United States

🇺🇸

South Florida Medical Research, Aventura, Florida, United States

🇺🇸

Clinical Research Center of Flordia, Pompano Beach, Florida, United States

and more 2 locations

A Study to Evaluate the Denosumab in Healthy Adults

Phase 1
Conditions
Interventions
First Posted Date
2018-02-09
Last Posted Date
2018-02-09
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
32
Registration Number
NCT03427853
Locations
🇨🇳

Peking University People's Hospital, Beijing, Xicheng District, China

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

Phase 1
Completed
Conditions
Interventions
First Posted Date
2017-11-30
Last Posted Date
2018-01-04
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
20
Registration Number
NCT03357796
Locations
🇺🇸

Clinilabs, Inc., Eatontown, New Jersey, United States

Pilot BA Study of New LY03005 vs Pristiq

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-12-09
Last Posted Date
2017-03-20
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
20
Registration Number
NCT02988024
Locations
🇺🇸

Clinilabs, Inc., Eatontown, New Jersey, United States

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-04-05
Last Posted Date
2016-12-05
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
28
Registration Number
NCT02728947
Locations
🇺🇸

CNS Network, Long Beach, California, United States

🇺🇸

Atlanta Center for Medical Research, Atlanta, Georgia, United States

🇺🇸

MD Clinical, Hallandale Beach, Florida, United States

Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-11-13
Last Posted Date
2016-12-05
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
20
Registration Number
NCT02603770
Locations
🇺🇸

NRC Research Institute, Orange, California, United States

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

First Posted Date
2014-10-22
Last Posted Date
2015-10-21
Lead Sponsor
Luye Pharma Group Ltd.
Target Recruit Count
58
Registration Number
NCT02271412
Locations
🇺🇸

PRA Health Sciences, Marlton, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath